Regarding visfatin, an adipokine with arguably insulin-mimetic effects (33) and which is highly expressed in visceral fat (34, 35) appears to be upregulated in patients with obesity (36) and type 2 diabetes mellitus (37). Here, INS is linked to Obesity.